Innogenetics

From Wikipedia, the free encyclopedia

Innogenetics building in Zwijnaarde.

Innogenetics is a Belgium-based international biopharmaceutical company, with headquarters in Ghent, Belgium. The company has two divisions: a specialty diagnostics business, and a therapeutics business that develops therapeutic vaccines. Christiaan De Wilde is the CEO of the company.

1 History
2 See also
3 Source
4 External links

[edit] History

Innogenetics was founded on 18 July 1985, by Erik Tambuyzer, Hugo Van Heuverswyn and Rudi Mariën. In 1992, the company launched the first commercial tests for cystic fibrosis in Europe (INNO-LiPA CFTR) and in 1993 the first commercial test for Hepatitis C virus (HCV) genotyping worldwide (INNO-LiPA HCV). In 1995, the first commercial Alzheimer’s disease research test for hTau was launched (INNOTEST hTau Ag). In 1998, the company launched the first commercial Alzheimer’s disease research test for β-Amyloid and in 2002 the first commercial test for Hepatitis B virus (HBV) genotyping (INNO-LiPA HBV Genotyping).

The company was one of the first biotech companies to be listed on a European stock exchange, in 1996 it was the first biotech company listed on EASDAQ, now NASDAQ Europe. Innogenetics currently has its shares traded on Euronext Brussels. On 1 October 2007, the therapeutics division was separated into a new company GENimmune NV for the development of immune therapeutics.

[edit] See also

[edit] Source

Annual report
Jannes G, De Vos D., A review of current and future molecular diagnostic tests for use in the microbiology laboratory, Methods Mol Biol. 2006;345:1-21.
Tortoli E, Marcelli F.,Use of the INNO LiPA Rif.TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility, Eur J Clin Microbiol Infect Dis. 2007, Jan;26(1):51-5.